Late recurrence of lupus nephritis in a renal transplant recipient: response to mycophenolate mofetil.
Clinically significant recurrence of lupus nephritis in the renal allograft is low, with an incidence of 1 to 3%, and usually occurs within the first 6 years after transplantation. We report an unusual case of a patient with end-stage renal disease caused by lupus nephritis who received a kidney transplant from a living relative; 13 years later, the patient had a severe recurrence of diffuse proliferative lupus nephritis. The patient relapsed after receiving intravenous cyclophosphamide therapy and had a partial response to oral mycophenolate mofetil. In this report we review the risk factors for the recurrence of the systemic lupus erythematosus in the kidney graft and the anti-lupus activity of mycophenolate mofetil.
Ahuja
T S
TS
Department of Medicine, University of Texas Medical Branch Galveston, USA. tahuja@utmb.edu
Boughton
J
J
Weiss
V
V
Memon
A
A
Remmers
A
A
Rajaraman
S
S
D000328:Adult; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000473:pathology; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000601:surgery*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D012008:Recurrence; D013997:Time Factors
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid